Vinge Logotype
Svenska English 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge represents Symrise in connection with its mandatory offer on Probi
Mandate

Vinge represents Symrise in connection with its mandatory offer on Probi

February 06, 2014

Symrise AG has, after having acquired shares corresponding to approximately 30.03 per cent of the votes in Probi AB (publ), launched a mandatory offer to the shareholders in Probi, with an offered price of SEK 40.10 per share. Vinge represents Symrise in connection with the mandatory offer.

Symrise is a global supplier of fragrances, flavourings, cosmetic, active ingredients, and raw materials as well as functional ingredients. The company’s share is listed on the Frankfurt Stock Exchange and the market capitalisation of Symrise is EUR 4 billion.

Probi is a research-driven biotechnology company focused on the global probiotics market. Through Probi’s research Probi has developed probiotics with well-documented beneficial health effects. The company’s share is listed on NASDAQ OMX Stockholm, Small cap and the market capitalisation of Probi is approximately MSEK 375.

Vinge’s team primarily consists of Jesper Schönbeck, Oskar Belani, Joakim Hagberg and Sabina Börjesson.

Related

Vinge advises Axcel VI and Currentum in connection with the acquisition of Elprojekt Skandinavien

 Vinge advises Axcel VI and the Currentum Group in connection with the acquisition of Elprojekt Skandinavien. The company provides complete electrical installations throughout Sweden, focusing on new construction of logistics properties, production facilities, residential buildings and office buildings. Elprojekt Skandinavien had a revenue of SEK 316 million in 2024.
June 23, 2025

Vinge advises Meribel Pharma Solutions

 Vinge advises Meribel Pharma Solutions in connection with the sale of a production facility specialising in the manufacture of antibiotics to Apotek Produktion & Laboratorier AB ("APL").
June 23, 2025

Vinge has advised Hansa Biopharma in connection with a directed share issue of approx. SEK 232 million and restructuring of debt financing

 Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue, through which Hansa raises gross proceeds of approx. SEK 232 million, and restructuring of debt financing. As part of such debt restructuring, Hansa has in conjunction with the directed share issue set-off debt corresponding to approximately USD 14.9 million of its total debt amount.
June 23, 2025